Posters

Vitrectomy with subretinal tissue plasminogen activator and anti-VEGF intravitreal injection for submacular haemorraghes: Retrospective case series of 10 cases

Poster Details

First Author: A.Herranz Cabarcos SPAIN

Co Author(s):    I. Alarcon   D. Vilaplana Blanch   A. Marinez Palmer                       

Abstract Details



Purpose:

To assess the efficacy of small-gauge vitrectomy with subretinal recombinant tissue plasminogen activator (rtPA) and anti-VEGF intravitreal injection for submacular haemorrhages and to identify the factors associated with visual outcome, based on our experience during the past 6 years.

Setting:

Hospital de l'Esperança - Parc de Salut Mar

Methods:

A retrospective case series was performed, including all patients who had small-gauge vitrectomy with subretinal rtPA and anti-VEGF intravitreal injection for submacular haemorrhages. Ethiology was not taken into account.

Results:

A total of 10 eyes of 10 patients were included in the study. Mean age was 84.72± 8.5 years, and 7 of 10 patients (70%) were women. Surgery was performed on average 9.77±4.87 days after the onset of symptoms, and patients were observed for a follow-up period of 12months. On average, visual acuity improved 0.00875 decimal in pacients with AMD versus the VA improvement of 0.095decimal in patients with macroaneurysms between presentation and last follow-up. Visual acuity improved in 7 patients (70.0%), remained unchanged in 1 patient (10.0%), and worsened in 2 patients (20.0%).

Conclusions:

Small-gauge vitrectomy with subretinal rtPA and intravitreal anti-VEGF is effective for improving visual acuity in patients with submacular haemorrhages in general. Small haemorrhage area, prompt surgery and aetiology different from AMD are associated with better final visual acuity.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy